



OFFICE OF THE SECRETARY
PATIENT-CENTERED OUTCOMES
RESEARCH TRUST FUND

PROJECT REPORT

FINAL REPORT

Evidence-Based Measures for Chronic Disease Outcomes: A Review of Available Measures for Emerging Sickle Cell Disease Therapies

Prepared for
The Office of the Assistant Secretary for Planning and Evaluation (ASPE)
at the U.S. Department of Health and Human Services

by
NORC at the University of Chicago

October 2026

OFFICE OF THE ASSISTANT SECRETARY FOR PLANNING AND EVALUATION

The Assistant Secretary for Planning and Evaluation (ASPE) advises the Secretary of the U.S. Department of Health and Human Services (HHS) on policy development in health, disability, human services, data, and science; and provides advice and analysis on economic policy. ASPE leads special initiatives; coordinates the Department's evaluation, research, and demonstration activities; and manages cross-Department planning activities such as strategic planning, legislative planning, and review of regulations. Integral to this role, ASPE conducts research and evaluation studies; develops policy analyses; and estimates the cost and benefits of policy alternatives under consideration by the Department or Congress.

OFFICE OF THE SECRETARY – PATIENT-CENTERED OUTCOMES RESEARCH TRUST FUND

The Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) was established as part of the 2010 Patient Protection and Affordable Care Act and is charged to build data capacity for patient-centered outcomes research. Coordinated by ASPE on behalf of the Department, OS-PCORTF has funded a rich portfolio of projects to meet emerging U.S. Department of Health and Human Services policy priorities and fill gaps in data infrastructure to enhance capabilities to collect, link, and analyze data for patient-centered outcomes research. For more information, visit <https://aspe.hhs.gov/collaborations-committees-advisory-groups/os-pcortf>.

This report was funded by the Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) under Contract Number HHSP233201500048II of the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE). The work was carried out by NORC at the University of Chicago and ASPE. The authors are solely responsible for this document's contents, findings, and conclusions, which do not necessarily represent the views of HHS, ASPE, or NORC. Readers should not interpret any statement in this product as an official position of ASPE or of HHS.

Suggested Citation: Zott C, Anderson JP, Wiltz JL, Peterson C, Dullabh P. Evidence-Based Measures for Chronic Disease Outcomes: A Review of Available Measures for Emerging Sickle Cell Disease Therapies. Washington, D.C.: Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. October 2026.

CONTRIBUTING AUTHORS

Courtney Zott, MPH, Research Scientist, NORC

Jesse P. Anderson, DrPH, Informatics Health Scientist, Office of Health Policy, ASPE

Jennifer L. Wiltz, MD, MPH, Chief Medical Officer, Office of Health Policy, ASPE

Caroline Peterson, MPH, Senior Research Associate II, NORC

Prashila Dullabh, MD, Vice President and Senior Fellow, NORC

PROJECT OFFICERS AND PROJECT LEADERSHIP

Jesse P. Anderson, DrPH, ASPE

Marcos Trevino, MPH, ASPE

Jennifer L. Wiltz, MD, MPH, ASPE

Prashila Dullabh, MD, NORC

ACKNOWLEDGEMENTS

Titilope Fasipe, MD, PhD, Texas Children's Hospital

Julie Kanter, MD, University of Alabama at Birmingham

Khristina Reid, Virginia Sickle Cell Network

Table of Contents

Executive Summary	1
1. Introduction	2
1.1 Background	2
1.2 Objectives and Structure of the Report	3
2. Methods	4
2.1 Environmental Scan	4
2.2 Engagement with Subject Matter Experts	5
3. Results	5
3.1 Recommended PRO Endpoints for SCD Clinical Trials	6
3.2 PRO Endpoints in SCD Cell-Based Gene Therapy Clinical Trials	7
4. Discussion	13
4.1 Limitations of the Environmental Scan	16
5. Conclusion	16
Appendix A. Environmental Scan Methods	18
Appendix B. Characteristics of PROMs in Inventory	21
Appendix C. PROMs Developed Specifically for SCD	22

Table of Exhibits

Exhibit 1. Typical Treatment Pathway for Autologous Cell-Based Gene Therapies for Sickle Cell Disease, Adapted from Sharma (2024)	3
Exhibit 2. Article Selection Process	5
Exhibit 3. PRO Endpoints and PROMs Recommended by FDA/ASH Expert Panels	6
Exhibit 4. Characteristics of SCD Cell-Based Gene Therapy Clinical Trials Incorporating or Planning to Incorporate PROMs	7
Exhibit 5. PROMs and Concepts Assessed in SCD Cell-based Gene Therapy Clinical Trials ^a	9
Exhibit 6. Domains Covered in PROMs Used to Assess Health-Related Quality of Life	10
Exhibit 7. Number of PROMs Used in SCD Cell-based Gene Therapy Clinical Trials Developed for SCD	12
Exhibit 8. Number of Months Post-Treatment at Which PROMs Were Assessed in SCD Cell-Based Gene Therapy Clinical Trials	12
Exhibit 9. PROMs Used in Related Clinical Contexts That Could be Adapted to Assess Treatment Side Effects	15

Glossary

Term	Definition
Cell-Based Gene Therapy	An ex vivo approach, such as those recently approved by the U.S. Food and Drug Administration (FDA), ¹ in which hematopoietic stem cells are removed from the body, modified with new genetic instructions, and then returned to the body to begin producing healthy blood cells. ²
Clinical Outcome Assessment (COA)	A term used by the FDA to indicate a measure that describes or reflects how a patient feels, functions, or survives. Types of COAs recognized by the FDA include: 1) patient-reported outcome measures (PROMs), 2) observer-reported outcome (ObsRO) measures, 3) clinician-reported outcome (ClinRO) measures, and 4) performance outcome (PerfO) measures. ³
Concept of Interest (COI)	What is specifically measured by a COA to help understand how a medical product affects a meaningful aspect of health. The COI operationalizes a broader meaningful aspect of health into a construct that can be validly and reliably assessed within a clinical trial. ⁴
Endpoint	The measurement that will be statistically compared among treatment groups to assess the effect of treatment and that corresponds with the clinical trial's objectives, design, and data analysis. Endpoints may be designated as primary, secondary, or exploratory. ⁵ They can be based on laboratory or clinical data (e.g., biomarkers, survival) or on COAs, including PROMs.
Hematopoietic Stem Cell Transplantation (HSCT)	Hematopoietic stem cell transplantation, sometimes referred to as bone marrow transplant, involves administering healthy hematopoietic stem cells to patients with dysfunctional or depleted bone marrow. ⁶
Meaningful Aspect of Health (MAH)	What a medical product should affect to provide a clinical benefit to patients. COA scores can be interpreted as direct measures of the MAH or specific aspects of the MAH depending on the concept of interest they intend to study. ²
Patient-Reported Outcome (PRO)	A measurement based directly on a patient's report about their health without interpretation by anyone else including a clinician. ³
PRO Endpoint	An endpoint for which a PROM is used as the measure (versus a physiologic biomarker or other type of measure).
Patient-Reported Outcome Measure (PROM)	Tools or instruments used to assess PROs. ⁷
PROM Domain	A distinct component or sub-concept of a broader health concept measured by a PROM. ⁵
Sickle Cell Disease	A serious inherited blood disorder caused by a mutation in the hemoglobin subunit beta (HBB) gene, leading to abnormal, sickle-shaped red blood cells that block blood flow and cause severe health complications. ⁸

Executive Summary

Background. The United States (U.S.) Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation (ASPE) supports intradepartmental efforts to build data capacity for patient-centered outcomes research and to improve evidence generation for healthcare decision-making. ASPE contracted with NORC at the University of Chicago to conduct an environmental scan to explore the patient-reported outcome measures (PROMs) that could be used in new and emerging sickle cell disease (SCD) therapies. In SCD clinical trials, PROMs may be used as clinical outcome assessments (COAs) to assess patient-reported outcome (PRO) endpoints related to how patients feel and function as a result of treatment and to inform regulatory evaluations. The development of new cell-based gene therapies introduces substantially different treatment processes, risks, and expected outcomes that may not be fully captured by PROMs used in trials for traditional SCD treatments.

Objective. This project identified, reviewed, and synthesized evidence on PROMs that could be used as COAs in clinical trials for new SCD cell-based gene therapies to support therapeutic submissions to the U.S. Food and Drug Administration (FDA).

Methods. We conducted an environmental scan to identify and characterize PROMs that could be used in clinical trials for both existing and emerging cell-based gene therapies for SCD. Activities included a peer-reviewed literature search using PubMed and EMBASE and a targeted web scan of grey literature, with a focus on sources documenting PROM use in trials (e.g., ClinicalTrials.gov) and SCD-focused advocacy organization websites. Records were screened using a two-stage process: title/abstract screening followed by full-text review. Information from eligible sources was abstracted into a structured inventory. Three subject matter experts (two clinicians and one patient advocate) provided input on the scan's scope and interpretation of preliminary findings, and reviewed project deliverables.

Results. The environmental scan identified that PRO endpoints historically recommended in SCD trials by the American Society of Hematology and the FDA primarily focused on specific aspects of pain, affect, and function. In contrast, PRO endpoints used in trials of cell-based gene therapies for SCD addressed some of these same areas but more commonly emphasized global measures of health-related quality of life with substantial variability in the domains assessed across measures. The scan identified nine clinical trials of cell-based gene therapies that incorporated or planned to incorporate PRO endpoints. These trials used or planned to use 22 unique PROMs to assess 11 different concepts of interest. After health-related quality of life, the most frequently measured concepts were pain intensity and overall pain. The 13 PROMs used to measure health-related quality of life captured approximately 30 different domains, many of which covered aspects of pain, affect, and function. Most of the identified PROMs (17) were not developed specifically for use among people with SCD; instead, many were developed as generic measures that could be used to assess the experiences of people with a wide range of health conditions.

Conclusion. The environmental scan of PROMs used as COAs in SCD cell-based gene therapy clinical trials identified a wide range of instruments in a rapidly evolving field. The variability in PROMs and domains assessed likely reflects the emerging nature of these therapies and the predominance of early-phase (Phase 1/2) trials, in which investigators are still determining which measures are most appropriate and sensitive for capturing the effects of treatment. Future work to advance PROM use should focus on prioritizing measures that more precisely capture functional outcomes important to patients; tailoring instruments to individuals' unique functional baselines; developing or adapting instruments to better capture treatment side effects and safety; and extending assessments to identify long-term outcomes.

1. Introduction

Purpose of the Report

The United States (U.S.) Department of Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) coordinates intradepartmental projects under the Office of the Secretary – Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) portfolio that build data capacity for conducting patient-centered outcomes research (PCOR). These efforts support data infrastructure initiatives that improve evidence generation for patient and provider health care decision-making. Understanding what is important to patients in clinical trials and assessing safety and efficacy through high-quality measurement is key to regulatory decision-making.⁴ However, a persistent challenge in regulatory evaluation is whether existing measurement tools adequately capture patient-relevant concepts of interest and are fit-for-purpose for their intended context of use. As new therapies emerge, there is a need for tools that can accurately capture new patient experiences. ASPE contracted with NORC at the University of Chicago (NORC) to conduct an environmental scan to explore the patient-reported outcome measures (PROMs) that could be used in new and emerging sickle cell disease (SCD) therapies.

1.1 Background


Sickle Cell Disease Treatment Overview

More than 100,000 people in the U.S. live with SCD, an inherited hemoglobin disorder caused by mutations in the β -globin.^{9,10} Individuals with SCD experience significant sickness related to severe acute and chronic pain, cardiovascular disease, and organ damage, contributing to lower life expectancy.^{11,12} Traditional SCD treatment has historically focused on disease management through pharmacological therapy, such as hydroxyurea, to prevent vaso-occlusive crises causing pain and other complications; non-pharmacological approaches such as cognitive behavioral therapy for the psychosocial management of chronic pain; and blood transfusions.^{13,14} Allogeneic hematopoietic stem cell transplantation (HSCT) has been the only cure option since the late 1980s but is limited by donor availability and serious treatment-related risks, such as graft-versus-host disease and the need for long-term immunosuppression.¹⁵

Cell-Based Gene Therapy Overview

More recently, curative strategies have evolved beyond hematopoietic stem cell transplantation to autologous cell-based gene therapies that modify or replace genes in patients' own stem cells.¹⁶ Two autologous cell-based gene therapies were approved by the U.S. Food and Drug Administration (FDA) in 2023: Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel).^{17,18} These cell-based gene therapies eliminate donor-related risks such as graft-versus-host disease. However, they still introduce treatment burdens and toxicities related to stem cell mobilization and collection, myeloablative conditioning chemotherapy, and inpatient infusion and post-therapy monitoring, and they have unknown long-term effects.¹ **Exhibit 1** shows the typical treatment pathway for these new therapies. Additional cell-based gene therapies remain under clinical investigation, with trials evaluating various gene-editing and gene-addition approaches.^{19,20}

Exhibit 1. Typical Treatment Pathway for Autologous Cell-Based Gene Therapies for Sickle Cell Disease, Adapted from Sharma (2024)²¹



PROs for Sickle Cell Disease Overview

The substantially different treatment processes, risk profiles, and expected outcomes associated with cell-based gene therapies¹⁶ compared to past SCD treatments necessitate careful evaluation of whether existing PRO endpoints and PROMs adequately capture both treatment-related burden and benefit. It remains uncertain whether PROMs historically used in SCD trials fully reflect the short-term toxicities, recovery trajectory, and long-term uncertainties associated with cell-based gene therapy, or whether additional or adapted measures are required to support PRO endpoints for this emerging treatment.

Clinical Outcomes Assessment Overview

When evaluating whether to approve a new medical product, the FDA assesses whether the product demonstrates a clinically significant treatment effect on a meaningful aspect of health (MAH). This determination is made by estimating the treatment effect on an endpoint intended to reflect the MAH. Endpoints are precisely defined outcome measures used to assess the safety or efficacy of an intervention in a clinical trial. They can be designated as primary, secondary, or exploratory depending on their role in supporting regulatory decision-making and the specific objectives of the trial.²²

To support patient-centered drug development and evaluation, the FDA encourages the use of clinical outcome assessments (COAs) as endpoints in clinical trials.³ PROMs are one of four types of COAs (alongside clinician-reported, observer-reported, and performance outcome measures).^{23,24} For a PROM-based COA to be relied upon as evidence in regulatory decision-making, it must be fit for purpose within its defined context of use as a trial endpoint.⁴ A COA is considered fit for purpose when there is sufficient evidence to support the validity of the interpretation of its scores as measuring the specified concept of interest in the defined population and setting. This includes evidence supporting content validity, reliability, construct validity, and the ability to detect change.⁴

1.2 Objectives and Structure of the Report

The primary goal of this project was to identify, review, and analyze PROMs that could be used as COAs in support of trials for new cell-based gene therapies submitted to the FDA for SCD, and to provide a comprehensive inventory of these measures.

This project is guided by the following research questions:

- 1. What PROMs exist for use in SCD treatment, and what symptom domains do they assess?

2. Have these existing measures been established for use in new and emerging therapies developed for SCD? What additional or adapted PROMs may be needed to align with these evolving therapies and their symptom profiles?
3. What evidence exists on the measurement properties of these PROMs (e.g., reliability, validity) to inform their potential suitability as COAs?
4. What is the available evidence about the use of these measures as COAs in support of clinical drug and biologics trials for new therapeutics submitted to the FDA?

The report is intended to support the FDA and other federal partners, academic and independent researchers, and pharmaceutical sponsors involved in the conduct of clinical trials by providing a comprehensive resource to inform the selection and use of PROMs. The subsequent sections of the report are organized as follows: the **Methods** section provides an overview of the data collection methods, including the implementation of an environmental scan and engagement with subject matter experts (SMEs); the **Results** section describes the PROMs identified through these methods and their characteristics; the **Discussion** section describes gaps and opportunities to develop or adapt PROMs for use in SCD cell-based gene therapy trials; and the **Conclusion** section summarizes findings and future directions. The report also contains supplementary appendices described in the following sections.

2. Methods

We conducted an environmental scan to identify PROMs, gaps, and opportunities for adapting and developing PROMs, which involved two key activities. First, we identified PROMs through a literature review. Next, we sought feedback on the literature review findings from clinician and patient advocate SMEs.


2.1 Environmental Scan

An environmental scan was conducted to identify and enable the characterization of PROMs that could be used to support clinical trials for both existing and emerging cell-based gene therapies for SCD. Additionally, the scan identified gaps and opportunities in the PROMs currently available and areas where PROMs can be adapted or developed to support understanding of the patient experience with these new therapies.

To complete the scan, we first conducted a peer-reviewed literature search using PubMed and EMBASE, supplemented by a targeted web scan of grey literature to identify additional relevant PROMs. We prioritized grey literature sources that focused on the use of PROMs in clinical trials, including Clinicaltrials.gov and various SCD-focused advocacy organization websites. **Exhibit 2** illustrates the article selection process. After the removal of duplicate articles, literature identified through the review underwent a two-step screening process: an initial title and abstract review, followed by a full-text review for eligibility. We applied search terms and inclusion/exclusion criteria as detailed in **Appendix A, Exhibits A2 and A3**, respectively.

Following full-text review, we abstracted information from included peer-reviewed and grey literature into a spreadsheet inventory (**Appendix A, Exhibit A4**). The inventory was accessible to all team members to ensure transparency and collaborative input.

Exhibit 2. Article Selection Process



2.2 Engagement with Subject Matter Experts

We engaged with three SMEs – two clinicians, one of whom has lived experience with SCD, and a patient advocate – to guide the environmental scan. The SMEs first provided input on the general literature review search strategy through semi-structured interviews. SMEs then shared feedback on and further contextualized the literature review findings through the asynchronous review of tables and figures with preliminary results. These tables and figures were later incorporated into the final report. Finally, SMEs reviewed the full report and provided further feedback that was incorporated into the final version.

3. Results

This section begins with findings related to PRO endpoints and PROMs recommended for SCD clinical trials, followed by those used in trials that specifically study new cell-based gene therapies. PROs refer to reports of health status, symptoms, functioning, or treatment experiences provided directly by patients, while PROMs are the instruments used to assess these outcomes. In clinical trials, endpoints are the measurements used to evaluate and statistically compare treatment effects; PRO endpoints are endpoints for which a PROM is used as the measure. Further details regarding these PROMs are available in the inventory accompanying this report on [\[placeholder for webpage link\]](#). **Appendix B** describes the characteristics of each of the identified PROMs that are included in the inventory.

3.1 Recommended PRO Endpoints for SCD Clinical Trials

The FDA and the American Society of Hematology (ASH) convened expert panels in 2019 that identified core PRO endpoints for SCD clinical trials aligned with SCD's major symptoms and impacts.²⁵ These included PRO endpoints related to pain (intensity, interference/impact, and behavior), affect (depression/negative emotional impact and fatigue), and functioning (social, physical, and cognitive function; self-efficacy; and occupational function).²⁵

The PROMs recommended by the panel to measure each PRO endpoint are shown in **Exhibit 3**. Additional endpoints recommended by SMEs are also included. Instruments from the Patient-Reported Outcomes Measurement Information System (PROMIS), Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-ME), and Pediatric Quality of Life Inventory (PedsQL) were recommended for many of the PRO endpoints.

Exhibit 3. PRO Endpoints and PROMs Recommended by FDA/ASH Expert Panels

PRO Endpoint	Recommended PROM
Pain	
Intensity: The magnitude or severity of perceived pain. ²⁶	- Numeric Rating Scale (NRS)²⁷ - Visual Analog Scale (VAS)²⁸
Interference/impact: The extent to which pain hinders engagement with physical, cognitive, emotional, cognitive, and recreational activities, as well as sleep and enjoyment in life. ²⁹	- PROMIS Pain Interference³⁰ - ASCQ-ME Pain Impact³¹ - PedsQL Pain Impact³² - PedsQL Pain and Hurt³² - PROMIS-Physical Function³³ (SME recommendation)
Behavior: Behaviors people with pain engage in that communicate to others that they are experiencing pain (e.g., verbal complaints, facial expressions). ³⁴	PROMIS Pain Behavior³⁵
Affect	
Depression/negative emotional impact: A generalized tendency towards experiencing negative feelings such as anger, hostility, depression, grief, and anxiety. ³⁶	- PedsQL SCD Module Emotions³² - ASCQ-ME Emotional Impact³⁷ - PROMIS Depression³⁸ - PROMIS Anxiety³⁹
Fatigue: An extreme sense of tiredness and lack of energy that can interfere with a person's usual daily activities. ⁴⁰	- PROMIS Fatigue⁴¹ - PedsQL Fatigue³²
Function	
Emotional/social, physical, cognitive domains: Emotional/social: An individual's ability to effectively interact and communicate in social settings while managing and monitoring their emotions.⁴² Physical: The ability to carry out activities that require physical actions, ranging from self-care to more complex activities that require a combination of skills, often within a social context.²⁹ Cognitive: The performance of the mental processes of perception, learning, memory, understanding, awareness, reasoning, judgment, intuition, and language.⁴³	- PROMIS⁴⁴ - ASCQ-ME³¹ - PedsQL³² - Canadian Occupational Performance Measure⁴⁵

Occupational status: The socioeconomic status associated with an individual's occupation. ⁴⁶	• PhenX question on employment status⁴⁷ • World Health Organization (WHO) Health and Work Performance Questionnaire⁴⁸
Self-efficacy: An individual's subjective perception of their capability to perform in a given setting or to attain desired results. ⁴⁹	• Sickle Cell Self-Efficacy Scale⁵⁰ • Patient Activation Measure (SME recommendation)⁵¹

ASCQ-Me = Adult Sickle Cell Quality of Life Measurement Information System; PedsQL = Pediatric Quality of Life Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System

3.2 PRO Endpoints in SCD Cell-Based Gene Therapy Clinical Trials

This section describes the PRO endpoints and PROMs used specifically in cell-based gene therapy clinical trials.

3.2.1 Characteristics of SCD Cell-Based Gene Therapy Clinical Trials

Nine clinical trials of cell-based gene therapies for SCD incorporated or planned to incorporate PRO endpoints. Five of these trials stem from three sponsored drug development programs, while four trials were investigator-initiated (**Exhibit 4**). Peer-reviewed publications reporting PRO endpoint results were identified for only two trials. PRO endpoints for the other seven trials were identified through conference presentation abstracts, publicly available clinical trial protocols, and/or results published by sponsors.

Exhibit 4. Characteristics of SCD Cell-Based Gene Therapy Clinical Trials Incorporating or Planning to Incorporate PROMs

Study Name	PRO Endpoint	PROM(s) Used
1. A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease (CLIMB SCD-121)^{a,52,53} Sponsor: Vertex Pharmaceuticals and CRISPR Therapeutics Study Population: Patients 12 to 35 years of age Phase: Phase 1/2/3	Health-related quality of life	- ASCQ-ME ³¹ - EQ-5D-5L ⁵⁴ - EQ-5D-Y ⁵⁵ - EQ VAS ⁵⁶ - PedsQL ³² - PedsQL SCD Module ⁵⁷
	HSCT-related impact	FACT-BMT Bone Marrow Transplantation Subscale ⁵⁸
	Pain intensity	NRS ²⁷
2. A Long-term Follow-up Study in Participants Who Received CTX001 (CLIMB SCD-131)⁵⁹ Sponsor: Vertex Pharmaceuticals and CRISPR Therapeutics Study Population: Patients 12 to 35 years of age Phase: Phase 3	Health-related quality of life	- ASCQ-ME ³¹ - PedsQL SCD Module ⁵⁷ - FACT-BMT ⁵⁸
	Pain	FLACC ⁶⁰
	Pain intensity	- FACES ⁶¹ - NRS ²⁷

3. Gene Transfer for Patients With Sickle Cell Disease (ARU-1801_Ph1_01) ⁶² Sponsor: Independent with partial funding from Aruvant Sciences Study Population: Patients 18 to 45 years of age Phase: Phase 1/2	Health-related quality of life	ASCQ-ME ³¹
4. A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease (HGB-206) ^{b,63,64} Sponsor: Bluebird Bio Study Population: Patients 12 to 50 years of age Phase: Phase 1/2	Health-related quality of life	PROMIS-57 ⁶⁵
	Pain intensity	NRS ²⁷
5. A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease (HGB-210) ⁶⁴ Sponsor: Bluebird Bio Study Population: Patients 12 to 50 years of age Phase: Phase 3	Health-related quality of life	PROMIS-57 ⁶⁵
	Pain intensity	NRS ²⁷
6. Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (CADPT03A12101) ^{c,66,67} Sponsor: Novartis Pharmaceuticals Study Population: Patients 2 to 40 years of age Phase: Phase 1/2	Pain Impact	ASCQ-ME Pain Impact ⁶⁸
	Sleep impact	ASCQ-ME Sleep Impact ⁶⁹
	Emotional impact	ASCQ-ME Emotional Impact ³⁷
	Fatigue	PROMIS Fatigue ⁴¹
	Physical function	PROMIS Physical Function ³³
7. Efficacy Safety Study of Gene Therapy for Sickle Cell Disease (SCD) Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA (DREPAMIR) ⁷⁰ Sponsor: Independent Study Population: Patients 12 to 35 years of age Phase: Phase 1/2	Physical ability	GPAQ ⁷¹
	Patient health	MOS-SF-36 ⁷²
	Fatigue	FACIT-Fatigue ⁷³
	Health-related quality of life	- PROMIS (unspecified) ^{d, 44} - PedsQL ³²
8. A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP) ⁷⁴ Sponsor: Independent Study Population: Patients 13 to 40 years of age Phase: Phase 2	Health-related quality of life	- PROMIS Fatigue ⁴¹ - PROMIS Pain Interference ³⁰ - PROMIS Sleep Disturbance ⁷⁵
9. Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies ⁷⁶	Health-related quality of life	- PedsQL ³² - MOS-SF-36 ⁷²

Sponsor: Independent Study Population: Patients 13 to 40 years of age Phase: Phase 1		
---	--	--

^a This study was conducted as part of the drug development program that supported FDA approval of Casgevy.

^b This study was conducted as part of the drug development program that supported FDA approval of Lyfgenia.

^c This trial was terminated early for business reasons, and the analysis of PRO endpoints could not be performed due to lack of available data.

^d This unspecified instrument is counted as one instrument in subsequent results.

ASCQ-Me = Adult Sickle Cell Quality of Life Measurement Information System; EQ-5D-5L = EuroQol 5 Dimension 5 Level; EQ-5D-Y = EuroQol 5 Dimension 5 Level Youth; EQ VAS = EuroQol Visual Analogue Scale; FACES = Wong-Baker FACES® Pain Rating Scale; FACIT = Functional Assessment of Chronic Illness Therapy; FACT-BMT = Functional Assessment of Cancer Therapy – Bone Marrow Transplantation; FLACC = Face, Legs, Activity, Cry, Consolability Scale; GPAQ = Global Physical Activity Questionnaire; MOS-SF = Medical Outcomes Study Questionnaire Short Form; NRS = Numeric Rating Scale; PedsQL = Pediatric Quality of Life Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System

3.2.2 PROMs Used in SCD Cell-based Gene Therapy Clinical Trials


The identified trials used or planned to use 22 unique PROMs to assess 11 different conceptsⁱ (**Exhibit 5**). The most frequently measured concept was health-related quality of life (assessed 19 times across trials, reflecting both use of multiple instruments within a trial and assessment across different trials), followed by pain intensity (five assessments). Trials used or planned to use 13 unique PROMs to measure health-related quality of life.

The trials that were part of the drug development programs for Casgevy and Lyfgenia assessed health-related quality of life, pain intensity, and HSCT-related impact, but the endpoints were ultimately not used to support labeling claims.^{77,78} Across trials, PRO endpoints were most frequently designated as secondary or exploratory. No trial included a PRO endpoint explicitly as a primary endpoint.ⁱⁱ

Exhibit 5. PROMs and Concepts Assessed in SCD Cell-based Gene Therapy Clinical Trials^a

ⁱ In most cases, the concept of interest underlying PRO endpoints, as defined within the FDA’s COA framework, was not explicitly stated in published reports. Concepts were therefore characterized based on the PROM used, the specific score analyzed (e.g., total or domain score), and the endpoint description provided in the trial publication or protocol.

ⁱⁱ Some trials included vaso-occlusive crises (VOC), or pain crises, as primary endpoints. VOCs are identified based on patient-reported symptoms and experiences and thus could be conceptualized as a PRO, although they are not typically reported as such.



^a A PROM may be counted multiple times if a trial generated multiple publications that reported the results of the PROM (e.g., a publication on the primary trial results and a separate health-related quality of life publication).

^b Patient health was assessed using the MOS-SF-36, which captures multiple aspects of health, including physical functioning, role limitations, social functioning, pain, mental health, vitality, and general health perceptions.

*The Numeric Rating Scale (NRS) was the PROM used in all trials that included a PRO endpoint measuring pain intensity.

ASCQ-Me = Adult Sickle Cell Quality of Life Measurement Information System; EQ-5D-5L = EuroQol 5 Dimension 5 Level; EQ-5D-Y = EuroQol 5 Dimension 5 Level Youth; EQ VAS = EuroQol Visual Analogue Scale; FACES = Wong-Baker FACES® Pain Rating Scale; FACIT = Functional Assessment of Chronic Illness Therapy; FACT-BMT = Functional Assessment of Cancer Therapy – Bone Marrow Transplantation; FLACC = Face, Legs, Activity, Cry, Consolability Scale; GPAQ = Global Physical Activity Questionnaire; HrQoL = Health-related quality of life; HSCT = Hematopoietic stem cell transplantation; MOS-SF = Medical Outcomes Study Questionnaire Short Form; NRS = Numeric Rating Scale; PedsQL = Pediatric Quality of Life Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System

Health-Related Quality of Life

The 13 PROMs used to measure health-related quality of life capture approximately 30 different domains (**Exhibit 6**). Many of the domains capture aspects of pain, affect, and function that were identified as particularly salient for SCD by the 2019 expert panels convened by ASH and FDA.²⁵ The PROMs also capture nine other domains, including sleep, mobility, and general health. Many of these domains overlap with concepts that are also evaluated on their own in trials (e.g., pain and pain intensity).

Exhibit 6. Domains Covered in PROMs Used to Assess Health-Related Quality of Life

ASH/FDA Domain Category	Domains in Health-Related Quality of Life PROMs*
Pain	Pain impact (2)

	• Pain • Pain interference (2) • Pain intensity • Pain and hurt • Pain management and control • Pain episodes
Affect	• Depression (2) • Anxiety (2) • Fatigue (2)
Function	• Physical function (2) • Emotional function (2) • Social function (2) • Ability to participate in social roles and activities • Emotions • School function • Functional well-being • Physical well-being • Social/family well-being
Other	• Sleep disturbance (2) • Sleep impact • Mobility • Self-care • Usual activities • Worry • Stiffness impact • Communication • Additional concerns


**Domains covered by more than one PROM are noted with the relevant number of instruments in which they appear in parentheses. All other domains are captured by only one PROM.*

Applicability of PROMs to SCD Populations

Most of the identified PROMs (n=16) were developed for general use (**Exhibit 7**) for assessing the experiences of people with a wide range of health conditions, though this does not necessarily limit their suitability for use in SCD trials. One PROM, the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT), was originally developed for use among cancer patients and was used in SCD clinical trials to assess health-related quality of life and side effects of gene therapy treatment.

PROMs developed specifically for use in SCD included four ASCQ-ME instruments and the Peds-QL SCD Module. A list of PROMs developed for SCD is provided in **Appendix C**. Complete information on which PROMs were and were not developed for SCD is available in the accompanying inventory.

Exhibit 7. Number of PROMs Used in SCD Cell-based Gene Therapy Clinical Trials Developed for SCD




Timing of PRO Endpoint Assessments

The timing of PRO endpoint assessment is a critical design consideration in trials of cell-based gene therapies for SCD, as the treatment process may introduce short-term toxicities that affect how patients feel and function, and meaningful improvements may emerge gradually over time. From a regulatory perspective, the timing of assessment also affects whether a PRO endpoint can demonstrate clinically meaningful benefit.

All studies assessed the change in the PROM score from baseline over time as the endpoint. The earliest assessment of change occurred at three months post-treatment for most endpoints where timing was specified, except for HSCT-related impact (**Exhibit 8**). Most studies continued PROM assessments at approximately six-month intervals for two years. Publications generally reported the earliest timepoint at which a change in the PROM score met established thresholds for meaningful change.

The duration that PROMs were assessed generally reflected the trial phase. Phase 1 and 2 studies, which comprised seven of the nine identified trials, typically included follow-up of two years or less consistent with their focus on safety and short-term efficacy. The only Phase 3 trials identified were for Casgevy and Lyfgenia, and these extended follow-up beyond two years (up to five years for Casgevy and up to four years for Lyfgenia) as these trials are intended to confirm longer-term safety and efficacy. PRO endpoints planned for assessment focused on health-related quality of life, pain intensity, and overall pain. Limited information was available regarding how baseline was operationalized. When described, “baseline” was generally defined as a timepoint prior to initiation of the gene therapy treatment process. However, SMEs noted that in practice, baseline data is at times collected *after* patients begin to receive chronic transfusions as part of traditional SCD treatment, which could influence accuracy of PRO results.

Exhibit 8. Number of Months Post-Treatment at Which PROMs Were Assessed in SCD Cell-Based Gene Therapy Clinical Trials



^a Patient health was assessed using the MOS-SF-36, which captures multiple aspects of health, including physical functioning, role limitations, social functioning, pain, mental health, vitality, and general health perceptions.

4. Discussion

Along with identifying PROMs used in clinical trials for SCD cell-based gene therapies, the environmental scan and SME discussions identified key gaps and challenges in current practices. This section outlines specific opportunities to strengthen PROM use, each corresponding to an identified gap or challenge.

One identified challenge is that PROMs used in clinical trials assess a wide range of concepts, limiting outcome comparisons. Though SMEs felt the concepts assessed were generally appropriate, they noted that the variability in concepts assessed and PROMs selected may limit comparability across trials. SMEs discussed the need to prioritize PRO endpoints that more directly capture functional impacts and the extent to which symptoms interfere with daily life. They identified aspects of functioning that are highly important to individuals with SCD, including the ability to attend school, maintain friendships, maintain education or employment, engage in social activities, and manage daily responsibilities. In addition, they emphasized that additional aspects of pain beyond its mere presence or intensity of pain may be more informative, such as the extent to which pain interferes with daily functioning and feelings of anxiety around pain episodes.

One potential solution is to prioritize PRO endpoints that assess functional impacts, such as physical function, pain interference, pain catastrophizing, social well-being, and sleep disturbance. SMEs noted that physical function is important because it directly assesses a patient's ability to participate in activities of daily living. PROMIS-Physical Function was highlighted as a key instrument for assessing this concept. They viewed pain interference, which is the degree to which pain disrupts functioning, as a more meaningful measure because it captures the degree to which patients are able to function due to or in spite of their pain. They also stressed the importance of measuring pain catastrophizing, which is a negative cognitive-affective response to anticipated or actual pain that significantly impacts patients'

daily lives.⁷⁹ They emphasized social well-being as it directly captures many aspects of life important to SCD patients (e.g., relationships, education). Lastly, they noted that sleep disturbance is a critical measure due to its relationship to overall functioning.

Another challenge is PROMs often do not account for individual baselines. SMEs also noted that many of the PROMs used in the identified trials may not accurately detect functional “improvements,” as they do not often account for each patient’s unique baseline of health due to SCD. For example, some patients may have lived with more severe pain and fatigue for most of their lives while others may have milder symptoms going into treatment.

One potential solution is to develop or adapt PROMs to capture patients’ expectations for daily functioning. For example, instruments could capture what patients expect to accomplish in their daily lives and then assess the frequency with which they are able to meet those expectations over time. This would shift measurement toward evaluating whether individuals with SCD can function in alignment with their own goals, rather than against population norms. The HAQ-DI and the Sickle Cell World Assessment Survey (SWAY)⁸⁰ were highlighted by SMEs as instruments that assess patients’ experience of the impact of SCD on their daily lives.

Additionally, many PROMs are not able to detect meaningful short-term change. PRO endpoints were not explicitly employed as primary endpoints in any identified trial, consistent with their historical role in SCD clinical trials.^{81,82} SMEs noted one reason may be that existing PROMs, particularly for measuring health-related quality of life, may not be sensitive enough to detect meaningful changes relevant to SCD patients within the span of a clinical trial. In SCD, SMEs noted that health-related quality of life is heavily influenced by personal circumstances – which rarely change – and the pre-existing impacts of the disease. Even following curative treatment, patients may continue to experience residual symptoms (e.g., from pre-existing organ damage) or psychological impacts (e.g., from the major identity shift to not having SCD) that delay their perception of improved quality of life. As a result, PROM outcomes may not fully align with the short-term clinical benefits expected from curative treatment.

One potential solution is to draw on PROMs that are more responsive to near-term changes in symptoms and functioning. SMEs highlighted several PROMs from conditions with measurable short-term symptom changes as promising starting points. Examples include the Brief Pain Inventory (BPI)⁸³ and Patient Global Impression of Change (PGIC)⁸⁴ used in fibromyalgia trials; the Psoriatic Arthritis Impact of Disease (PsAID) instrument⁸⁵ used in psoriatic arthritis trials; the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function subscales⁸⁶ used in osteoarthritis trials; and the Health Assessment Questionnaire Disability Index (HAQ-DI)⁸⁷ used in rheumatoid arthritis trials. Improving the responsiveness of PROMs in SCD could better align PROs with expected treatment effects and may over time support stronger integration into regulatory decision-making.

Another challenge is clinical trials rarely use PROMs to assess treatment side effects and safety. Only one identified trial used a PROM to assess the impact of the gene therapy treatment itself, using the FACT-BMT, an instrument originally developed for oncology populations. While FACT-BMT captures important treatment-related concerns such as chemotherapy side effects (e.g., appetite loss, fatigue, concentration difficulties, skin problems), no trials incorporated PROMs to assess patient experience during other key treatment phases such as stem cell mobilization, apheresis, and post-infusion recovery.

Although the FDA has issued guidance that PROMs should not replace traditional safety and adverse event reporting and are typically used as

descriptive/exploratory endpoints,⁹⁴ understanding the patient-reported experience of new cell-based gene therapy treatment remains important.

One potential solution is to draw on PROMs used to assess side effects in related clinical contexts where patients undergo similar intensive, multi-phase treatments. PROMs utilized in hematopoietic stem cell transplantation for SCD and oncology-related gene therapy trials can serve as starting points (**Exhibit 9**), as these treatments similarly involve conditioning chemotherapy regimens and extended recovery periods. These PROMs commonly assess domains related to treatment-related symptoms and adverse events, as well as emotional distress, anxiety, depression, post-traumatic stress, fatigue, and sleep disturbance.

However, SMEs emphasized a critical distinction between SCD and oncology populations that has important implications for adapting PROMs used in this area.

Unlike many cancer patients—who typically experienced previous good health—many individuals with SCD have never known life without chronic pain, fatigue, and functional limitations. As a result of this different baseline, they may experience treatment-related side effects differently. This suggests that PROMs used in cancer trials, while useful starting points, may require additional cognitive testing and adaptation to ensure validity for SCD populations undergoing cell-based gene therapy.

A final identified challenge is few trials assessed long-term treatment impacts using PROMs. The environmental scan showed that PROMs were administered at relatively consistent intervals (e.g., every 3–6 months) but typically only for up to two years following treatment given the emerging nature of the treatment and the prevalence of Phase 1 and Phase 2 studies. Only two trials planned to assess PROMs beyond two years. Notably, no trials used or planned to use PROMs to assess potential long-term side effects such as impacts on fertility, mental health, or secondary cancer risk—outcomes that SMEs identified as critical to patients and families considering these treatments. SMEs noted that PROMs may yet not exist for some of these concepts.

SMEs noted that timing of PROM administration for long-term follow-up is particularly important given that toxicities from the treatment (e.g., from conditioning regimens) may temporarily worsen PROs and

Exhibit 9. PROMs Used in Related Clinical Contexts That Could be Adapted to Assess Treatment Side Effects

Symptomatic burden and adverse events:

- Patient-Reported Outcome Version of the Common Terminology for Adverse Events (PRO-CTCAE)⁸⁸
- Edmonton Symptom Assessment Scale⁸⁹

Emotional distress, anxiety, and/or depression:

- State Trait Anxiety Inventory (STAI)⁹⁰
- Hospital Anxiety and Depression Scale⁸⁹
- Patient Health Questionnaire (PHQ)-9^{89,91}
- Profile of Mood States (POMS)⁹⁰
- National Comprehensive Cancer Network (NCCN) Distress Thermometer⁹²

Post-traumatic stress:

- PTSD Checklist-Civilian Version (PCL-C)^{89,91}
- Impact of Event Scale-Revised⁹⁰

Fatigue and sleep disturbance:

- Functional Assessment of Cancer Therapy – Fatigue (FACT-Fatigue)⁹¹
- Pediatric Quality of Life (PedsQL) Inventory Multidimensional Fatigue Scale⁹³
- Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance⁹²

meaningful improvements may take longer to emerge in this population due to existing impacts of the disease and the need to adjust psychologically after treatment.

In addition to long-term follow-up studies, one solution is to incorporate PROMs important to patients into other research designs, such as comparative effectiveness and observational studies. Given the FDA's requirement for extended (i.e., 15-year) post-treatment follow-up for cell-based gene therapies, there is a critical need for PROMs that can capture long-term outcomes important to patients. This includes treatment satisfaction; lasting effects of the treatment; continued effects of existing damage from SCD despite being "cured"; psychological implications related to identity shifts post-treatment; and potential unknown, delayed impacts of curative therapy. Alternative study designs, which have greater flexibility in choice of outcomes, could incorporate these PROMs and support the generation of more comprehensive evidence on long-term patient experiences.

Such studies could also incorporate other outcomes across the treatment process that may not be considered direct measures of treatment benefit by the FDA but are significant aspects of the patient and caregiver experience, such as anxiety, guilt, fear, and cost of treatment. They may also provide opportunities to not only measure PROs but to also offer solutions or interventions in response to concerning findings. For example, SMEs indicated it would be critical to provide counseling if patients reported depression or to offer guidance on tapering off opioids as pain improves.

4.1 Limitations of the Environmental Scan

This report is subject to some limitations. First, while a significant amount of peer-reviewed literature was reviewed to identify cell-based gene therapy clinical trials for SCD that incorporated PROMs, this treatment remains emerging, and many trials have not yet published full results. As a result, the analysis had to rely more heavily on grey literature sources, including Clinicaltrials.gov listings, manufacturer protocols, and conference abstracts. Consequently, some trials that used or planned to use PROMs may not have been captured if such information was not publicly available at the time of review. In addition, reliance on protocols reflects planned, rather than actual, study conduct. PROM selection and timing may evolve over the course of a trial and thus may differ from what is ultimately reported in protocols. Second, the findings are based on a relatively small number of trials within a rapidly evolving field. As such, patterns in PROM use may reflect the early stage of trials for cell-based gene therapies rather than established practices and should be interpreted accordingly as the evidence base continues to mature.

5. Conclusion

The environmental scan of PROMs used as COAs in SCD cell-based gene therapy clinical trials identified a wide range of instruments in a rapidly evolving field, with several opportunities to strengthen and standardize their use as these therapies undergo longer-term evaluation. While many PROMs are being incorporated in trials, important gaps remain in both the instruments and their application. These include substantial variability that may limit comparability across trials; limited ability to capture meaningful functional improvements; and insufficient assessment of treatment-related side effects, burdens, and long-term impacts.

These challenges point to several promising opportunities for advancing PROM use as COAs in future cell-based gene therapy clinical trials, as well as other research designs (e.g., comparative effectiveness research). These include prioritizing measures that more precisely capture functional outcomes

important to patients; tailoring instruments to individuals' unique functional baselines; developing or adapting instruments to better capture treatment side effects and safety; and extending assessments to identify long-term outcomes. Continued methodological development is essential to advancing these opportunities and generating more comparable and patient-centered evidence, ultimately supporting more comprehensive understanding of the benefits and risks of cell-based gene therapies for SCD. Although broader adoption of PRO endpoints will likely also depend on FDA regulatory guidance and sponsor priorities, this report aims to reduce practical barriers by providing FDA and other federal agencies, researchers, and sponsors with a comprehensive inventory and review of available PROMs and identifying opportunities to strengthen and standardize their use, thereby supporting more consistent PRO assessment in future clinical trials.

Appendix A. Environmental Scan Methods

Exhibit A1. Websites Prioritized During Grey Literature Search

Sources of Information on PROs in Clinical Trials
ClinicalTrials.gov
FDA's Clinical Outcome Assessment Compendium
FDA's Clinical Outcome Assessment Qualification Program Submissions
The PROTEUS (Patient-Reported Outcomes Tools: Engaging Users and Stakeholders) Consortium
Clinical Trials – Gene Therapy Trial Browser
National Associations/Non-Profit Organizations Focused on SCD
American Society of Hematology (ASH)
Sickle Cell Disease Association of America (SCDAA)
American Academy of Pediatrics (AAP)
American Public Health Association (APHA)
American Society of Pediatric Hematology/Oncology (ASPHO)
Sickle Cell Disease Foundation
Sick Cells
OneSCDVoice
American Society of Gene + Cell Therapy
General PRO Measure Resources
PhenX Toolkit
HealthMeasures
Cell-Based Gene Therapy Manufacturers' Materials
Vertex Pharmaceuticals Press Releases
Genetix Biotherapeutics

Exhibit A2. Literature Search Terms

Cell-Based Gene Therapy Trials

Search Term Category	Example Terms
SCD	Sickle cell disease, sickle cell anemia, sickle cell trait
PROs	Patient-reported outcome, patient-reported outcome measure, PROM, quality of life, survey
Clinical Trials/Study Context	Clinical trial, interventional study, Phase 1, Phase 2, Phase 3, observational study, quality improvement
Cell-Based Gene Therapies	gene therapy, cell therapy, genetic therapy, gene editing, CRISPR, lovocel, autotemcel, exacel

Other Relevant Clinical Contexts

Search Term Category	Example Terms
Disease	• HSCT: Sickle cell disease, sickle cell anemia, sickle cell trait • Rheumatoid arthritis: fibromyalgia, psoriatic arthritis, osteoarthritis
PROs	Patient-reported outcome, patient-reported outcome measure, PROM, quality of life, survey
Clinical Trials/Study Context	Clinical trial, interventional study, Phase 1, Phase 2, Phase 3, observational study, quality improvement
Treatment	• HSCT: Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation • Gene Therapy: gene therapy, cell therapy, genetic therapy, gene editing, CRISPR

Exhibit A3. Literature Search Inclusion and Exclusion Criteria

Category	Inclusion Criteria	Exclusion Criteria
Publication Year	Peer-reviewed journal articles: 2015-present Grey literature: 2015-present	Peer-reviewed journal articles: Before 2015 Grey literature: Before 2015
Document Type	Peer-reviewed journal articles: Clinical trials, observational studies, quality improvement (QI) programs, scoping/systematic reviews of clinical trials or QI programs Grey literature: Clinical trial registrations, reports, working papers, evaluation studies, white papers, conference proceedings, presentations, case studies, fact sheets, issue briefs, government documents, and manufacturers' trial reporting materials/monitoring updates	Grey literature: Opinion pieces
Language	English	Non-English
Source	Academic, expert, evaluator	News outlet
Population	SCD patients, patients receiving cell-based gene therapies (including oncology-related gene therapies), patients undergoing hematopoietic stem cell transplantation for SCD;	Patients not receiving cell-based gene therapies or treatments involving comparable conditioning chemotherapy and extended recovery periods; patients with conditions not identified by SMEs as relevant to the review.
Focus	Research with or concerning clinical trials, observational studies, or quality improvement programs that evaluate cell-based gene therapies or PRO endpoints for SCD cell-based gene therapies or clinically relevant to them.	Studies or databases that only focus on genetic or biomedical research and do not include a discussion of PROs. Also, studies that only involve qualitative data. Focus primarily on non-SCD chronic conditions without direct relevance to cell-based gene therapy treatment.

Exhibit A4. Fields Included in Full Article Abstraction Form

Field Type/Category	Specific Fields
Resource Overview	• Article name • Source (e.g., PubMed, grey literature, web search) • Publication year • Citation
Study Overview	• Study design (e.g., randomized clinical trial, single-arm interventional study, observational study, other) • If other, describe study design • If clinical trial, trial phase • If clinical trial, was it FDA-regulated and/or funded? • If SCD gene therapy trial, was it funded by a pharmaceutical company? If yes, list name. • If SCD gene therapy clinical trial, list trial name (if applicable) • If clinical trial, list NCT number • Intervention type • Did study population include people with SCD (Yes/No) • If Yes, list SCD population type (e.g., children, adults) • If No, list study population (e.g., people with other health condition)
PROM Characteristics	• PROM name • PROM sub-measure(s) (if applicable) • Concept assessed • Symptom domains covered by PROM • PROM administration timepoint(s) • If clinical trial, role in study (e.g., primary or secondary endpoint, descriptive only) • Validated for use in patients with SCD (Yes/No)

Appendix B. Characteristics of PROMs in Inventory

Exhibit B1. PROM Characteristics Included in the Inventory

PROM Characteristics	
• PROM Name • Developer • Concepts measured • Developed specifically for SCD? (yes/no) • If no, condition for intended use • Validated for SCD? (yes/no) • Validated for other populations? • Source(s) of information on validation • Population for intended use • Data collection method and format	• Number of items • Time to complete • Administration mode • Response options • Recall period • Scoring • Weighting of items or domains • Conceptual framework of the PROM • Translation or cultural adaptation availability • Accessibility (copyright information)

Appendix C. PROMs Developed Specifically for SCD

PROM Name	Brief Description
Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-ME) (General)	A set of self-report instruments that evaluate and monitor the physical, mental, and social well-being of adults with sickle cell disease (SCD). ⁹⁵
ASCQ-ME Sleep Impact	A specific ASCQ-ME instrument that assesses the effect of SCD on getting to sleep, staying asleep, falling back to sleep after waking, and getting enough sleep.
ASCQ-ME Emotional Impact	A specific ASCQ-ME instrument that assesses the effect of SCD on a person's feelings and emotions, including worry, depression, and loneliness.
ASCQ-ME Pain Impact	A specific ASCQ-ME instrument that assesses the severity of pain and the extent to which the severe and unpredictable pain that characterizes SCD affects a person's ability to do things.
Pediatric Quality of Life (Peds-QL) SCD Module	A specific module of the Peds-QL patient reported outcome measure that measures SCD-specific health-related quality of life. ⁹⁶

References

- ¹ U.S. Food and Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. FDA News Release. August 3, 2023. Accessed March 9, 2026. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease>
- ² American Society of Gene & Cell Therapy. Understanding Cell and Gene Therapy: Conditions Treated – Blood Disorders: Sickle Cell Disease. 2023. Accessed March 9, 2026. <https://patienteducation.asgct.org/understanding-cell-gene-therapy/conditions-treated/blood-disorders/sickle-cell-disease>
- ³ U.S. Food and Drug Administration. Clinical Outcome Assessment (COA): Frequently Asked Questions. Accessed March 10, 2026. <https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions#COADefinition>
- ⁴ U.S. Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments – Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. October 2025. Accessed March 10, 2026. <https://www.fda.gov/media/159500/download>
- ⁵ U.S. Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Guidance for Industry. December 2009. Accessed March 10, 2026. <https://www.fda.gov/media/77832/download>
- ⁶ Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. In: StatPearls. StatPearls Publishing; 2026. Accessed March 10, 2026. <http://www.ncbi.nlm.nih.gov/books/NBK536951/>
- ⁷ Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). *Health Serv Insights*. 2013;6:61-68. doi:10.4137/HSI.S11093
- ⁸ World Health Organization. Sickle-Cell Disease. August 6, 2025. Accessed March 17, 2026. <https://www.who.int/news-room/fact-sheets/detail/sickle-cell-disease>
- ⁹ Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. May 15, 2024. Accessed December 4, 2025. <https://www.cdc.gov/sickle-cell/data/index.html>
- ¹⁰ Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. *J Hematol Oncol*. 2022;15(1):20. doi:10.1186/s13045-022-01237-z
- ¹¹ Jiao B, Johnson KM, Ramsey SD, Bender MA, Devine B, Basu A. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. *Blood Adv*. 2023;7(13):3276-3283. doi:10.1182/bloodadvances.2022009202
- ¹² American Society of Hematology. Quantifying the Life Expectancy Gap for People Living with Sickle Cell Disease. 2023. Accessed December 4, 2025. <https://www.hematology.org/newsroom/press-releases/2023/quantifying-the-life-expectancy-gap-for-people-living-with-sickle-cell-disease>
- ¹³ National Heart, Lung, and Blood Institute. Sickle Cell Disease Treatment. September 30, 2024. Accessed December 4, 2025. <https://www.nhlbi.nih.gov/health/sickle-cell-disease/treatment>
- ¹⁴ Williams H, Tanabe P. Sickle cell disease: a review of nonpharmacological approaches for pain. *J Pain Symptom Manage*. 2016;51(2):163-177. doi:10.1016/j.jpainsymman.2015.10.017
- ¹⁵ Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. *Front Physiol*. 2020;11:435. Published 2020 May 20. doi:10.3389/fphys.2020.00435
- ¹⁶ Kabrah SM. Emerging Gene Therapies in Sickle Cell Disease: A Comparative Review of Efficacy and Safety Against Standard Treatments. *J Blood Med*. 2025;16:493-507. doi:10.2147/JBM.S556513
- ¹⁷ U.S. Food and Drug Administration. CASGEVY. Updated February 21, 2024. Accessed March 10, 2026. <https://www.fda.gov/vaccines-blood-biologics/casgev>
- ¹⁸ U.S. Food and Drug Administration. LYFGENIA. Updated July 10, 2024. Accessed March 10, 2026. <https://www.fda.gov/vaccines-blood-biologics/lyfgenia>

- ¹⁹ CRISPR Medicine News. Sickle Cell Disease, SCD (NCT04819841). Updated May 20, 2025. Accessed March 10, 2026. <https://crisprmedicineneeds.com/clinical-trial/sickle-cell-disease-scd-nct04819841/>
- ²⁰ National Library of Medicine (US). Stem Cell Gene Therapy for Sickle Cell Disease. ClinicalTrials.gov identifier: NCT02247843. Updated April 17, 2024. Accessed March 10, 2026. <https://clinicaltrials.gov/study/NCT02247843>
- ²¹ Sharma A. How I treat sickle cell disease with gene therapy. *Blood*. 2024;144(26):2693-2705. doi:10.1182/blood.2024024519
- ²² U.S. Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. October 2022. Accessed March 10, 2026. <https://www.fda.gov/media/162416/download>
- ²³ U.S. Food and Drug Administration. Patient-reported outcomes and other clinical outcome assessments. January 30, 2025. Accessed December 4, 2025. <https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments>
- ²⁴ U.S. Food and Drug Administration. Clinical outcome assessment compendium. Accessed December 9, 2025. <https://www.fda.gov/drugs/development-resources/clinical-outcome-assessment-compendium>
- ²⁵ Farrell AT, Panepinto J, Carroll CP, et al. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. *Blood Adv*. 2019;3(23):3982-4001. doi:10.1182/bloodadvances.2019000882
- ²⁶ Jensen MP. Measuring pain intensity. In: Jensen MP, ed. *The Pain Stethoscope: A Clinician's Guide to Measuring Pain*. Springer Healthcare Ltd.; 2011:3-7. doi:10.1007/978-1-908517-43-2_2
- ²⁷ Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. *Br J Anaesth* 2008;101(1):17–24.
- ²⁸ Couper M, Tourangeau R, Conrad F, et al. : Evaluating the effectiveness of visual analog scales: A web experiment. *Soc Sci Comput Rev*. 2006;24:227-245
- ²⁹ Karayannis NV, Sturgeon JA, Chih-Kao M, Cooley C, Mackey SC. Pain interference and physical function demonstrate poor longitudinal association in people living with pain: a PROMIS investigation. *Pain*. 2017;158(6):1063-1068. doi:10.1097/j.pain.0000000000000881
- ³⁰ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Pain Interference Scoring Manual. February 23, 2021. Accessed March 10, 2026. https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Pain_Interference_Scoring_Manual.pdf
- ³¹ HealthMeasures. Adult Sickle Cell Quality of Life Measurement Information System: ASCQ-Me Scoring Manual. December 2017. Accessed March 10, 2026. https://www.healthmeasures.net/images/ASQMe/ASCQ-Me_Scoring_Manual.pdf
- ³² Varni JW. PedsQL™ (Pediatric Quality of Life Inventory™). Accessed March 10, 2026. <https://www.pedsq.org/>
- ³³ HealthMeasures. PROMIS: Physical Function. June 10, 2020. Accessed March 17, 2026. https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Physical_Function_Scoring_Manual.pdf
- ³⁴ Revicki DA, Chen WH, Harnam N, et al. Development and psychometric analysis of the PROMIS pain behavior item bank. *PAIN*. 2009;146(1):158-169. doi:10.1016/j.pain.2009.07.029
- ³⁵ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Pain Behavior Scoring Manual. July 19, 2019. Accessed March 10, 2026. https://www.healthmeasures.net/images/promis/manuals/PROMIS_Pain_Behavior_Scoring_Manual.pdf
- ³⁶ Negative Emotion. ScienceDirect Topics. Accessed March 16, 2026. <https://www.sciencedirect.com/topics/computer-science/negative-emotion>
- ³⁷ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Pain Behavior Scoring Manual. July 19, 2019. Accessed March 10, 2026. https://www.healthmeasures.net/images/promis/manuals/PROMIS_Pain_Behavior_Scoring_Manual.pdf

- ³⁸ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Depression Scoring Manual. February 28, 2019. Accessed March 10, 2026. https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Depression_Scoring_Manual.pdf
- ³⁹ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Anxiety Scoring Manual. March 1, 2019. Accessed March 10, 2026. https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Anxiety_Scoring_Manual.pdf
- ⁴⁰ Definition of fatigue. NCI Dictionary of Cancer Terms. February 2, 2011. Accessed March 16, 2026. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/fatigue>
- ⁴¹ HealthMeasures. Patient-Reported Outcome Measurement Information System: PROMIS Fatigue Scoring Manual. February 28, 2019. Accessed March 10, 2026. https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Fatigue_Scoring_Manual.pdf
- ⁴² Socioemotional Functioning - an overview. ScienceDirect Topics. Accessed March 16, 2026. <https://www.sciencedirect.com/topics/psychology/socioemotional-functioning>
- ⁴³ Cognitive Functioning. APA Dictionary of Psychology. Accessed March 16, 2026. <https://dictionary.apa.org/>
- ⁴⁴ HealthMeasures. PROMIS® (Patient-Reported Outcomes Measurement Information System). Accessed March 10, 2026. <https://www.healthmeasures.net/explore-measurement-systems/promis>
- ⁴⁵ COPM Inc. The Canadian Occupational Performance Measure (COPM). Accessed March 10, 2026. <https://www.thecopm.ca/>
- ⁴⁶ Occupational Status - an overview. ScienceDirect Topics. Accessed March 16, 2026. <https://www.sciencedirect.com/topics/social-sciences/occupational-status>
- ⁴⁷ PhenX Toolkit. Current Employment Status (#011300): PhenX Core Tier 2 Measure. RTI International; 2015. Accessed March 10, 2026. https://curesickle.org/system/files/PhenX_Core_Tier_2_Employment_status.pdf
- ⁴⁸ Harvard Medical School. Health and Work Performance Questionnaire (HPQ). Accessed March 10, 2026. <https://www.hcp.med.harvard.edu/hpq/>
- ⁴⁹ Self-Efficacy. APA Dictionary of Psychology. Accessed March 16, 2026. <https://dictionary.apa.org/>
- ⁵⁰ PhenX Toolkit. Self-efficacy in Sickle Cell Disease (Protocol ID: 820401). Published July 30, 2015. Accessed March 10, 2026. <https://www.phenxtoolkit.org/protocols/view/820401>
- ⁵¹ Cronin RM, Dorner TL, Utrankar A, et al. Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease. *Pain Med.* 2019;20(8):1464-1471. doi:10.1093/pm/pny194
- ⁵² Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. *New England Journal of Medicine.* 2024;390(18):1649-1662. doi:10.1056/NEJMoa2309676
- ⁵³ Sharma A, Locatelli F, Bhatia M, et al. Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. *Blood Adv.* 2025;9(24):6481-6490. doi:10.1182/bloodadvances.2025016701
- ⁵⁴ EuroQol. EQ-5D-5L. January 21, 2025. Accessed March 17, 2026. <https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/>
- ⁵⁵ EuroQol. EQ-5D-Y-3L. January 21, 2025. Accessed March 17, 2026. <https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-y-3l/>
- ⁵⁶ Chuang LH, Kind P, Kohlmann T, Feng YS. Exploring the origin and conceptual framework of the EQ VAS. *Qual Life Res.* 2025;34(8):2163-2173. doi:10.1007/s11136-025-03947-6
- ⁵⁷ PhenX Toolkit. Protocol – PedsQL Sickle Cell Disease Module. Accessed March 17, 2026. <https://www.phenxtoolkit.org/protocols/view/820202>

- ⁵⁸ FACIT Group. Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT). Accessed March 17, 2026. <https://www.facit.org/measures/fact-bmt>
- ⁵⁹ Vertex Pharmaceuticals Incorporated. A Long-term Follow-up Study in Participants Who Received CTX001. ClinicalTrials.gov Identifier: NCT04208529. Updated February 11, 2025. Accessed February 19, 2026. <https://clinicaltrials.gov/study/NCT04208529>
- ⁶⁰ MDCalc. The Face, Legs, Activity, Cry, and Consolability (FLACC) Scale. Accessed March 17, 2026. <https://www.mdcalc.com/calc/10545/face-legs-activity-cry-consolability-flacc-scale>
- ⁶¹ Wong-Baker FACES Foundation. Wong-Baker FACES Pain Rating Scale. Accessed March 17, 2026. <https://wongbakerfaces.org/>
- ⁶² Grimley M, Davies SM, Shrestha A, et al. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. *Nat Med.* 2025;31(7):2204-2212. doi:10.1038/s41591-025-03662-2
- ⁶³ Walters MC, Tisdale JF, Mapara MY, et al. Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. *Blood.* 2021;138(Supplement 1):7. doi:10.1182/blood-2021-146905
- ⁶⁴ Kanter J, Thompson AA, Kwiatkowski JL, et al. Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up. *Blood.* 2023;142(Supplement 1):1051. doi:10.1182/blood-2023-174229
- ⁶⁵ HealthMeasures. PROMIS-57 Profile. Accessed March 17, 2026. https://www.healthmeasures.net/index.php?option=com_instruments&view=measure&id=860&Itemid=992
- ⁶⁶ Sharma A, Boelens J-J, Cancio M, et al. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease: Protocol Supplement. *N Engl J Med.* 2023;389(9):820-832. doi:10.1056/NEJMoa2215643. Accessed February 19, 2026. https://www.nejm.org/doi/suppl/10.1056/NEJMoa2215643/suppl_file/nejmoa2215643_protocol.pdf
- ⁶⁷ Novartis. Study results synopsis for public disclosure: Study No. CADPT03A12101. Novartis Clinical Trial Results Database. Published 2025. Accessed March 13, 2026. <https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=18388>
- ⁶⁸ HealthMeasures. ASCQ-ME: List of Measures – Pain Impact. Accessed March 17, 2026. <https://www.healthmeasures.net/explore-measurement-systems/ascq-me/intro-to-ascq-me/list-of-measures>
- ⁶⁹ HealthMeasures. ASCQ-ME: List of Measures – Sleep Impact. Accessed March 17, 2026. <https://www.healthmeasures.net/explore-measurement-systems/ascq-me/intro-to-ascq-me/list-of-measures>
- ⁷⁰ National Library of Medicine (US). Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA. (DREPAMIR). ClinicalTrials.gov identifier: NCT07432867. Updated February 25, 2026. Accessed March 10, 2026. <https://clinicaltrials.gov/study/NCT07432867>
- ⁷¹ World Health Organization. Global Physical Activity Questionnaire (GPAQ). November 13, 2021. Accessed March 17, 2026. <https://www.who.int/publications/m/item/global-physical-activity-questionnaire>
- ⁷² Rand Health. 36-Item Short Form Survey (SF-36). Accessed March 17, 2026. <https://www.rand.org/health/surveys/mos/36-item-short-form.html>
- ⁷³ FACIT Group. Functional Assessment of Chronic Illness Therapy – Fatigue Scale. Accessed March 17, 2026. <https://www.facit.org/measures/facit-fatigue>
- ⁷⁴ Kohn D, Krishnamurti L, London WB, et al. A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP). Published online November 27, 2024. Accessed April 16, 2026. https://bmtctn.net/system/files/BMT%20CTN%202001_Protocol_v5.0_signed_2.pdf

- ⁷⁵ Patient-Reported Outcomes Measurement Information System. PROMIS sleep disturbance. HealthMeasures. February 19, 2021.
https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Sleep_Disturbance_Scoring_Manual.pdf
- ⁷⁶ Bauer D. An Adaptive Design Basket Trial of Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β -Hemoglobinopathies. clinicaltrials.gov; 2026. Accessed April 16, 2026.
<https://clinicaltrials.gov/study/NCT06647979>
- ⁷⁷ U.S. Food and Drug Administration. LYFGENIA (lovotibeglogene autotemcel) suspension for intravenous infusion: prescribing information. December 2023. Accessed March 10, 2026.
<https://www.fda.gov/media/174610/download>
- ⁷⁸ U.S. Food and Drug Administration. CASGEVY (exagamglogene autotemcel) suspension for intravenous infusion: prescribing information. December 2023. Accessed March 10, 2026.
<https://www.fda.gov/media/174615/download>
- ⁷⁹ Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother. 2009;9(5):745-758. doi:10.1586/ern.09.34
- ⁸⁰ Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). Am J Hematol. 2021;96(4):404-417. doi:10.1002/ajh.26063
- ⁸¹ Ataga KI. The challenge of clinical end points in sickle cell disease. Blood. 2023;142(24):2047-2054. doi:10.1182/blood.2023021220
- ⁸² Adiutori R, Capella B, Savre I, Chamberlain C, Bothorel S, Sherafat-Kazemzadeh R. Use of Patient-Reported Outcomes for Sickle-Cell Disease in Clinical Trials: Do they match with consensus-based core outcomes sets recommendations? Published online 2023. Accessed May 21, 2026. https://www.ispor.org/docs/default-source/euro2023/pro-and-corescdposter30oct2023128399-pdf.pdf?sfvrsn=5f039828_0
- ⁸³ Brief Pain Inventory (BPI). UT MD Anderson. Accessed April 10, 2026.
<https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/symptom-research/symptom-assessment-tools/brief-pain-inventory.html>
- ⁸⁴ Patient Global Impression of Change. PhenX Toolkit. Accessed April 10, 2026.
<https://www.phenxtoolkit.org/protocols/view/860801>
- ⁸⁵ Queiro R. Psoriatic Arthritis Impact of Disease (PsAID) questionnaire: closer to the all-in-one tool? Rheumatology (Oxford). 2023;62(11):3513-3515. doi:10.1093/rheumatology/kead209
- ⁸⁶ WOMAC Osteoarthritis Index. Physiopedia. Accessed April 10, 2026. https://www.physio-pedia.com/WOMAC_Osteoarthritis_Index
- ⁸⁷ Health Assessment Questionnaire Disability Index (HAD-QI). Physiopedia. Accessed April 10, 2026.
[https://www.physio-pedia.com/Health_Assessment_Questionnaire_Disability_Index_\(HAD-QI\)](https://www.physio-pedia.com/Health_Assessment_Questionnaire_Disability_Index_(HAD-QI))
- ⁸⁸ Bryant AL, Coffman E, Phillips B, et al. Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2020;28(3):1223-1231. doi:10.1007/s00520-019-04932-9
- ⁸⁹ Gao L, Nelson A, Barata A, et al. Prolonged Hospitalization for Hematopoietic Cell Transplantation: Characteristics, Risk Factors and Associations with Patient-Reported and Clinical Outcomes. Transplant Cell Ther. 2025;31(9):697.e1-697.e12. doi:10.1016/j.jtct.2025.05.026

- ⁹⁰ Runaas L, Hoodin F, Munaco A, et al. Novel Health Information Technology Tool Use by Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: Longitudinal Quantitative and Qualitative Patient-Reported Outcomes. *JCO Clin Cancer Inform*. 2018;2:1-12. doi:10.1200/CCI.17.00110
- ⁹¹ El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. *J Clin Oncol*. 2025;43(24):2700-2711. doi:10.1200/JCO-25-00378
- ⁹² Banerjee R, Huang CY, Dunn L, et al. Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. *JMIR Form Res*. 2022;6(3):e33701. Published 2022 Mar 4. doi:10.2196/33701
- ⁹³ Johnston D, Gerbing R, Alonzo T, et al. Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. *PLoS One*. 2015;10(4):e0125290. Published 2015 Apr 27. doi:10.1371/journal.pone.0125290
- ⁹⁴ U.S. Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry. Silver Spring, MD: U.S. Food and Drug Administration; October 2024. Accessed March 13, 2026. <https://www.fda.gov/media/149994/download>
- ⁹⁵ HealthMeasures. Available ASCQ-ME measures for adult self-report. August 21, 2025. Accessed April 20, 2026. <https://www.healthmeasures.net/explore-measurement-systems/ascq-me/intro-to-ascq-me/list-of-measures>
- ⁹⁶ MAPI Research Trust. Pediatric quality of life inventory sickle cell disease module. October 2025. Accessed April 20, 2026. <https://eprovide.mapi-trust.org/instruments/pediatric-quality-of-life-inventory-sickle-cell-disease-module>